Drug intelligence / Profile preview

NBG 030

Development stage: Preclinical
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

NBG 030 is a monoclonal antibody developed by NB Health Laboratory (NBHL) that targets the frizzled receptor. It is being investigated as an antifibrotic and antineoplastic agent, with potential applications in the treatment of fibrosis and cancer. The drug acts as a frizzled receptor antagonist, interfering with Wnt signaling pathways implicated in fibrotic diseases and tumorigenesis. As of August 2023, it remains in early research stages for both indications[1].

Targets

FZD (Frizzled receptor family)

Beyond the preview

Go deeper on NBG 030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG 030.

Explore the full profile